Dr. Mark Schiller to present PEER at American College of Private Physicians
22 sept. 2016 05h00 HE
|
MYnd Analytics, Inc.
LAS VEGAS, Sept. 22, 2016 (GLOBE NEWSWIRE) -- Dr. Mark Schiller, Medical Director - MYnd Analytics, will present “Disruptive Technology Gets Personal” on September 25, 2016 at the Annual...
MYnd Analytics Letter to Shareholders
21 sept. 2016 08h05 HE
|
MYnd Analytics, Inc.
MISSION VIEJO, Calif., Sept. 21, 2016 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (OTCQB:CNSO) To our shareholders: We appreciate your continued support. We have produced disruptive results for one...
Ocera Announces Management Transition
15 sept. 2016 16h05 HE
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Achillion Announces 100% SVR Reported in Janssen’s Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV
09 sept. 2016 06h15 HE
|
Achillion Pharmaceuticals, Inc.
- New data released today in abstract for upcoming EASL / AASLD Special Conference: New Perspectives in Hepatitis C Virus Infection – The Roadmap For Cure - - Janssen advancing triple combination...
Achillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement Workshop
06 sept. 2016 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the presentation of two posters which detailed novel preclinical research into...
OncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic Cancer
01 sept. 2016 08h00 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing...
Achillion to Present at Two Upcoming Investor Conferences
01 sept. 2016 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
Sponsors and CROs Agree That Integrating Statistical Modeling and Knowledge of Past Performance Into Feasibility Analyses Improves Accuracy of Results
30 août 2016 11h00 HE
|
Industry Standard Research
CARY, NC--(Marketwired - August 30, 2016) - A new report, Best Practices in Study Feasibility, from Industry Standard Research (ISR) reveals insights into how to successfully navigate many of the...
Specialized Patient Recruitment Firms Bring More Value to a Trial Than Adding Sites
16 août 2016 11h00 HE
|
Industry Standard Research
CARY, NC--(Marketwired - August 16, 2016) - A new report from Industry Standard Research (ISR), Best Practices in Patient Recruitment, shows that Sponsors and CROs agree, hiring a specialized patient...
Achillion Announces Upcoming Presentation of Interim Phase 2a Results From the Janssen Sponsored Trial of Odalasvir, AL-335 and Simeprevir at the European Association for the Study of the Liver (EASL) Special Conference
11 août 2016 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that interim results from an ongoing phase 2a clinical trial, being conducted by...